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Altered nitric oxide metabolism and increased oxygen free radical
activity in lead-induced hypertension: Effect of lazaroid therapy
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Altered nitric oxide metabolism and increased oxygen free radical
activity in lead-induced hypertension: Effect of lazaroid therapy. Chronic
exposure to low levels of lead results in sustained hypertension (HTN) in
humans and experimental animals. The mechanism of lead-induced HTN
remains unclear. We investigated the possible role of reactive oxygen
species (ROS) and their impact on nitric oxide (NO) metabolism in
lead-induced HTN. Male Sprague-Dawley rats were treated with lead (100
ppm in drinking water) for twelve weeks. They were then treated with
either the potent antioxidant, lazaroid (des-methyl-tirilazad, 5 mg/kg i.p.,
twice daily) (Pb-Lz group) or placebo (Pb group) for two weeks and
monitored for an additional two weeks. A group of normal animals served
as controls (N = 6 in each group). Lead administration resulted in marked
HTN together with a significant rise in plasma concentration of lipid
peroxidation product, malondialdehyde (MDA, reflecting increased ROS
generation) and a twofold reduction in urinary excretion of NO metabo-
lites, that is, total nitrates and nitrites (NOx). Lazaroid therapy led to
prompt normalization of blood pressure, plasma MDA and urinary NOx.
In contrast, blood pressure and plasma MDA remained elevated, and
recovery of urinary NOx excretion was slow with placebo therapy. No
significant difference was found in creatinine clearance between the study
groups during the observation period. Thus, chronic lead exposure
resulted in marked HTN coupled with increased ROS production and
decreased urinary NOx excretion. Administration of the potent antioxi-
dant, lazaroid, abrogated HTN and reversed the abnormalities of plasma
MDA and urinary NOx excretion, thus supporting the role of ROS in
lead-induced HTN in this model.
Chronic exposure to low levels of lead results in arterial
hypertension (HTN) in humans and in experimental animals
[1—5]. The underlying mechanism of lead-induced HTN has not
been fully elucidated. In a recent study, we found a significant
increase in plasma concentration of lipid peroxidation product,
malondialdehyde (MDA), in rats with lead-induced HTN [61. This
observation points to increased production of reactive oxygen
species (ROS) in the lead-treated animals. if true, increased ROS
can contribute to the associated HTN by a number of different
mechanisms. First, by a direct vasopressor effect as previously
demonstrated [7—9], and second, by inactivating nitric oxide (NO),
otherwise known as endothelium-derived relaxing factor (EDRF)
[10—13]. Moreover, ROS may depress NO generation by down-
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regulating NOS expression [141. In addition, lipid peroxidation by
ROS can lead to generation of vasoconstrictive arachidonic acid
peroxidation products, 8-epi prostaglandin F2 alpha (isopros-
tanes), which can further contribute to the rise in blood pressure
[15—18]. Based on these observations, we hypothesized that lead-
induced HTN may be, in part, due to increased generation of
ROS. The present study was designed to test this hypothesis. To
this end, rats with lead-induced HTN were treated with des-
methyl tirilazad (U-74389G), a lazaroid with potent antioxidant
properties. The results were compared with those observed with
the placebo treatment. The lead-treated animals exhibited in-
creased blood pressure, elevated plasma MDA concentration and
decreased urinary excretion of NO metabolites, that is, total
nitrates and nitrites (NOx). Lazaroid administration reversed
lead-induced HTN and restored plasma MDA concentration and
urinary NOx excretion to normal. These findings support the
hypothesis that lead-induced HTN in rat is largely mediated by
the associated increase in ROS.
METHODS
Study groups
Male Sprague-Dawley rats (Harlan Sprague Dawley Inc., Indi-
anapolis, IN, USA) with the average weight of 190 g were used.
They were allowed free access to regular rat chow (Purina Rat
Chow; Purina Mills, Brentwood, MO, USA) and water containing
100 ppm lead acetate for twelve weeks. At the end of this period,
lead-containing water was discontinued and replaced with dis-
tilled water. The animals were then randomized to lazaroid-
treated (Ph-Lz) and placebo-treated (Pb) groups. The animals in
the Pb-Lz group were given lazaroid (des-methyl-tirilazad, U-
74389G; Pharmacia-Upjohn Inc., Kalamazoo, MI, USA) 5 mg/kg
intraperitoneafly twice daily for two weeks and observed for an
additional two weeks. The Pb group received placebo injections
(5% dextrose in water) instead. A group of normal animals with
no lead exposure was included for comparison. Six animals were
included in each group.
Body weight was determined at baseline, and weeks 12, 14 and
16. Arterial blood pressure was monitored regularly using a rat tail
sphygmomanometer (Harvard Apparatus, South Natick, MA,
USA). Blood samples were obtained by orbital sinus puncture at
weeks 12, 14, 15 and 16. On each occasion, animals were placed in
individual metabolic cages, and a five-hour urine collection was
obtained (between 9 a.m. and 2 p.m.) over dry ice for measure-
ment of NO metabolites (N03 and NO2-). Blood lead content
was measured by atomic absorption spectrometry (Perkin-Elmer
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Model 305 equipped with graphite furnace; Perkin-Elmer Inc.,
Norwalk, CT, USA). Serum creatinine and creatinine clearance
were determined using standard laboratory methods.
Measurements of plasma and urine NO2 /N03 (NOx)
The amount of total nitrate and nitrite in the test samples was
determined by a modification of the procedure described by
Braman and Hendrix [19] using the purge system of a Sievers
Instruments Model 270B Nitric Oxide Analyzer (NOATM; Sievers
Instruments Inc., Boulder, CO, USA). Briefly, plasma samples
were first deproteinized using chilled 100% ethanol (plasma!
ethanol = vol!vol) before use. The urine samples were diluted
ten times in distilled water prior to analysis. A saturated solution
of VC13 in 1 M HC1 was prepared and filtered prior to use. Five
milliliters of this reagent were added to the purge vessel and
purged with nitrogen gas for 5 to 10 minutes prior to use. The
purge vessel was equipped with a cold water condenser and a
water jacket to permit heating of the reagent to 95°C using a
circulating water bath. The hydrochloric acid vapors were re-
moved by a gas bubbler containing —15 ml of 1 M NaOH. The gas
flow rate into the chemiluminescence detector was controlled
using a needle valve adjusted to yield a cell pressure of —7 torr.
The flow rate of nitrogen into the purge vessel was adjusted to
prevent vacuum distillation of the reagent.
Samples were injected into the purge vessel to react with the
VC13!HCI reagent which converted nitrate, nitrite and S-nitroso
compounds to NO. The NO produced was stripped from the
reaction chamber (by purging with nitrogen and vacuum) and
detected by ozone-induced chemiluminescence in the chemilumi-
nescence detector. The signal generated (NO peak and peak area)
was recorded and processed by a Hewlett Packard Model 3390
Integrator. In a typical assay, 5 /klof the test sample were injected
to the purge vessel, and all samples were run in triplicate.
A standard curve was constructed using various concentrations
of NO3 (5 to 100 /LM) relating the luminescence produced to the
given N03 concentrations of the standard solutions. The amount
of NO2 !N03 in the test sample was determined by interpola-
tion of the result into the standard curve.
Plasma MDA assay
Lipoperoxides in plasma were determined by HPLC measure-
ment of malondialdehyde-thiobarbituric acid (MDA-TBA) using
a modification of the method of Wong et al [20]. Briefly, a 50 l
aliquot of plasma was mixed with 0.75 ml 0.44 M H3P04, 0.25 ml
aqueous 42 mivi TBA and 0.45 ml H20, The mixture was heated in
a boiling water bath for 60 minutes. After cooling on ice, an equal
volume of alkaline methanol (50 ml methanol + 4.5 ml 1 N
NaOH) was added and centrifuged with a microcentrifuge for five
minutes. Supernatant (50 1.11) was then injected into HPLC
(SP8700; Spectra-Physics, San Jose, CA, USA) by a manually-
operated injector. An econosphere C18 column 5 .,4.6 X 250
mm (Ailtech Inc., Deerfield, IL, USA), and a guard column, 3.9 x
2.3 mm, packed with Bondapak Corasil C18 (37 to 50 j.tm
particle diameter) were used. Mobile phase was a mixture of 50
m phosphate buffer, pH 6.8, (600 ml) and methanol (400 ml).
The flow rate was set at 1 ml,'min and was monitored with a UV
detector at 532 nm. The peak retention time was 2.9 0.15
minutes. The concentration of plasma lipoperoxides was deter-
mined by interpolation of peak area into an SP4270 integrator
Fig. 1. Longitudinal measurements of mean arterial blood pressure in
placebo-treated animals with lead-induced HTN (A), lazaroid-treated
animals with lead-induced HTN (A) and the normal control group (0).
Lazaroid therapy was carried out for two weeks (weeks 13 and 14). #P <
001 versus other groups (ANOVA); p < 0.05 versus baseline value
(week 12); **P < 0.01 versus baseline value (week 12).
Groups Baseline Week 12 Week 14 Week 16
Control 188 10 438 17 443 17 446 11
Pb 190 10 447 15 452 13 453 12
Pb+Lz 191± 11 427±6 437±16 445±5
P values NS NS NS NS
(Spectra-Physics), which was calibrated with a tetramethoxypro-
pane standard.
Data analysis
Data are presented as mean SCM. Analysis of variance
(ANOVA), regression analysis and Student's t-test were used in
evaluation of the data as appropriate. P values equal to or less
than 0.05 were considered significant.
RESULTS
Effects of lead
As expected, blood pressure in the Pb group obtained at the
end of the twelve-week lead exposure period was significantly
higher than that found at baseline and in the control animals.
Despite discontinuation of lead exposure, blood pressure re-
mained elevated in the Pb group throughout the 16-week obser-
vation period (Fig. 1). There was no significant difference among
the study groups with respect to body weights obtained at baseline
weeks 12, 14 or 16 (Table 1). Likewise, no significant difference
was observed in either serum creatinine or creatinine clearance
between the study groups during the study period (Table 2).
Plasma MDA concentration increased by more than twofold in
the Pb group and remained elevated despite discontinuance of
lead exposure beyond week 12 (Fig. 2).
The Pb group exhibited more than a twofold reduction in
E
E
a)
Cl)(I)
00
.0
(U
a)
160
150
140
130
120
110
100
90
#
i .I.
•.-.---..I
..-4-,.
...
12 13 14 15 16
Time, weeks
Table 1. Body weights (grams) obtained at baseline, weeks 12, 14 and
16 in the normal control group, lead-treated animals (Pb) and lead plus
lazaroid-treated group (Pb + Lz)
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Groups Scr Ccr Sr Ccr
Control 0.57 0.06 1.93 0.16 0.53 0.05 2.15 0.45
Pb 0.54 0.06 1.68 0.23 0.46 0.01 2.33 0.22
Pb + Lz 0.51 0.06 1.66 0.20 0.49 0.02 2.28 0.61
I I I I
12 13 14 15 16
Time, weeks
Fig. 2. Longitudinal measurements of plasma concentration of malondi-
aldehyde (MDA) in placebo-treated rats with lead-induced HTN (A),
lazaroid-treated animals with lead-induced HTN (A) and the normal
control group (0). Lazaroid therapy was carried out for two weeks (weeks
13 and 14). #P < 0.01 versus other groups (ANOVA); **p < 0.01 versus
baseline value (week 12).
urinaly NOx excretion on week 12. Urinary NOx excretion
remained severely depressed despite removal of lead for two
weeks. Thereafter, it gradually rose reaching the normal value at
the end of week 16 (Fig. 3). The reduction in urinary NOx
excretion was not due to reduced renal clearance of NOx. This is
because lead exposure did not lower glomerular filtration rate and
did not raise plasma NOx concentration, which should have
occurred if the latter were the case.
Effect of lazaroid therapy
Administration of lazaroid for two weeks after discontinuation
of lead resulted in a steady decline in blood pressure to a value
which was significantly below that found in the untreated Pb group
and comparable to that of the control group. Blood pressure in
the Ph-Lz group remained normal during the two-week observa-
tion period after completion of lazaroid therapy (Fig. 1).
Lazaroid therapy resulted in normalization of plasma MDA
concentration in the Pb-Lz group. In contrast, plasma MDA
concentration remained markedly elevated in the Ph group
throughout the observation period (Fig. 2). As expected, blood
lead concentration was increased in the Pb group (17 9 j.tglliter
vs. undetectable quantity in the control group). Lazaroid therapy
did not significantly change blood lead concentration (22 6
#
12 13 14 15 16
Time, weeks
Fig. 3. Longitudinal measurements of urinary excretion (.4) and plasma
concentration (B) of NO metabolites, nitrates and nitrites (NOx), in
placebo-treated animals with lead-induced HTN (Pb, A), lazaroid-treated
animals with lead-induced HTN (Pb-Lz, A) and the normal control group
(0). Lazaroid therapy was carried Out for two weeks (weeks 13 and 14).
#P < 0.01 versus other groups (ANOVA); < 0.01 versus baseline
value (week 12); * < 0.05 versus Pb group.
j.tg/liter in the Pb-Lz group, P = NS vs. Pb group). Likewise,
lazaroid therapy did not affect glomerular filtration rate measured
as creatinine clearance (Table 2).
Urinary NOx excretion obtained after two weeks of lazaroid
therapy was twice that observed in the untreated Ph group and
comparable to that seen in the control group. Despite discontin-
uation of lazaroid therapy, urinary NOx excretion remained
normal in the Ph-Lz group. In contrast, the measurements ob-
tained in the untreated Ph group did not reach the normal value
until the end of week 16 (4 weeks after cessation of lead). Thus,
lazaroid therapy accelerated the restoration of normal urinary
NOx in the lead-treated animals, a process which was considerably
slower without intervention (Fig. 3). The accelerated rise in
urinary NOx excretion in the lazaroid-treated animals was not due
Table 2. Serum crcatinine (Sr) concentrations (mg/dl) and creatinine
clearance (Cr, mI/mm) measurements obtained during the study period
in lead-treated animals (Pb), lead plus lazaroid-treated animals (Pb +
Lz) and the normal control rats
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Fig. 4. Correlation between mean arterial blood pressure and plasma
MDA concentration in the study groups (•, control group; A, placebo-
treated animals with lead-induced HTN; andU, lazaroid-treated animals
with lead-induced HTN; [r = 0.84, P < 0.001J).
to enhanced glomerular clearance of these metabolites. This is
because lazaroid therapy did not raise glomerular filtration rate
and did not lower plasma NOx concentration.
Correlations
A significant direct correlation was found between blood pres-
sure and plasma MDA concentration in the entire study popula-
tion (r = 0.84, P < 0.001, Fig. 4). In contrast, blood pressure was
inversely related to the urinary NOx excretion rate (r =
—0.73,
P < 0.001). Likewise, plasma MDA concentration was negatively
related to urinary NOx excretion (r =
—0.54, P < 0.01).
DISCUSSION
Animals exposed to low levels of lead exhibited a significant rise
in arterial blood pressure which persisted after discontinuation of
lead exposure. However, as shown before, exposure to the given
levels of lead did not alter glomerular filtration rate as measured
by endogenous creatinine clearance. These observations are con-
sistent with those reported in the previous studies [4, 5]. The rise
in arterial blood pressure in the lead-treated animals was accom-
panied by an impressive twofold reduction in urinary NOx excre-
tion and a marked elevation of plasma MDA concentration. The
latter is indicative of increased ROS activity leading to enhanced
lipid peroxidation. The observed fall in urinary NOx excretion in
the lead-treated animals on week 12 is not due to reduced
glomerular NOx clearance. This is based on the fact that glomer-
ular filtration rate was similar in the study groups throughout the
study period. Moreover, the fall in urine NOx excretion was not
accompanied by a rise in plasma NOx concentration, which would
have occurred if impaired renal excretion were the cause. Like-
wise, similarity in body wt and food intake tends to exclude dietary
intake as a likely possibility. Thus, the reduction in urinary NOx
excretion on week 12 points to decreased NO production in the
lead-treated animals. If true, this could potentially contribute to
HTN in this model. Interestingly, blood pressure remained ele-
vated despite ultimate normalization of NOx excretion on week
16. This phenomenon may suggest that prolonged NO deprivation
can lead to sustained HTN, which may persist despite subsequent
restoration of normal NO availability. In fact, extended adminis-
tration of NOS inhibitor, NG monomethyl-L-arginine (L-
NMMA), has been shown to cause systemic HTN that persisted
after discontinuation of NOS blockade [21]. It is, therefore,
conceivable that impaired NO availability in lead-treated animals
could have acted in a similar manner. It should be noted that
normalization of urinary NOx may not necessarily denote normal
NO availability to vascular smooth muscle. For instance, en-
hanced inactivation of NO by ROS can potentially limit NO
availability despite normal NO production (and hence normal
NOx excretion). In fact, increased ROS generation is known to
depress NO availability by enhancing NO inactivation [10—13].
Moreover, administration of superoxide dismutase to catalyze
superoxide dismutation (which, in turn, reduces tissue superoxide
level and prolongs the half-life of NO) enhances spontaneous
NO-dependent vasorelaxation and restores EDRF response to
acetylcholine in the aorta preparations from the diabetic animals
[22, 23]. In addition, elevation of ROS, per Se, may contribute to
HTN through a direct effect on vascular reactivity [7—9] or by
promoting the formation of vasoconstrictive, 8-epi prostaglandin
F2 alpha from peroxidation of arachidonic acid [15—18].
The proposition that lead-induced HTN may be directly and/or
indirectly mediated by excess production of ROS is supported by
the observation that administration of lazaroid abrogated the
associated HTN and restored normal rate of urinary NOx excre-
tion. In this regard, administration of dimercaptosuccinic acid
(DMSA), a chelator with ROS scavenging properties, has been
shown to ameliorate lead-induced HTN in experimental animals
[41. However, DMSA therapy was accompanied by a reduction in
blood lead concentration in that study consistent with the chelat-
ing action of this compound [4]. Given the dual action of DMSA
as a lead chelator and an ROS scavenger, it is not possible to
convincingly ascribe the effect of DMSA to the latter action alone.
In contrast to DMSA, lazaroid administration reversed lead-
induced HTN without affecting blood lead concentration, pointing
to the important role of ROS. Further support for the role of ROS
comes from a series of recent experiments that showed significant
reduction in arterial blood pressure following intravenous infu-
sions of superoxide and hydroxyl radical scavengers (superoxide
dismutase and dimethylthiourea, respectively) in rats with lead
induced HTN but not in normal controls [241.
Lazaroids are nonglucocorticoid 21-aminosteroids that are po-
tent inhibitors of oxygen radical-induced, iron-catalyzed lipid
peroxidation [25]. They are highly lipophilic and as such are
preferentially distributed in the lipid hilayer of cell membranes. It
appears that the inhibitory effect of lazaroids on lipid peroxidation
is a consequence of their potent free radical scavenging action
coupled with their strong physicochemical interaction with the cell
membrane [26, 271. Preliminary studies suggest that lazaroids may
be effective in the management of acute central nervous system
injuries, cerebral ischemia, hemorrhagic shock, traumatic shock,
cardiopulmonary arrest, endotoxemia and ROS-mediated isch-
emia-reperfusion renal injury [28, 29]. The present study points to
yet another potential utility of the these compounds.
In conclusion, animals with lead-induced HTN exhibited a
marked reduction in urinary NOx excretion coupled with a
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significant rise in circulating level of lipid peroxidation product,
MDA. Normalization of MDA levels with the use of a potent
antioxidant, lazaroid, accelerated the restoration of normal uri-
nary NOx excretion and abrogated the associated HTN. Together,
these data suggest that lead exposure in this model promotes
generation of ROS that can raise blood pressure by either a direct
vasopressor action, increased NO inactivation or both. The data
further support the possible role of antioxidant therapy as an
adjunct in the treatment of lead-associated HTN.
Reprint requests to N.D. Vaziri, M.D., Division of Nephrology and
Hypertension, Department of Medicine, UI Medical Center, 101 The City
Drive, Orange, California 92868, USA.
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